• Anna Curley, Vidheya Venkatesh, Simon Stanworth, Paul Clarke, Timothy Watts, Helen New, Karen Willoughby, Rizwan Khan, Priya Muthukumar, and Alison Deary.
• Cambridge University Hospitals NHS Trust, Cambridge, UK.
• Neonatology. 2014 Jan 1; 106 (2): 102-6.

IntroductionNeonatal thrombocytopenia is a common and important clinical problem in preterm neonates. A trial assessing clinically relevant outcomes in relation to the different platelet count thresholds used to trigger transfusion has never been undertaken in preterm neonates with severe thrombocytopenia.ObjectivesPlatelets for Neonatal Transfusion - Study 2 (PlaNeT-2) aims to assess whether a higher prophylactic platelet transfusion threshold is superior to the lower thresholds in current standard practice in reducing the proportion of patients who have a major bleed or die up to study day 28.MethodsPlaNeT-2 is a two-stage, randomised, parallel-group, superiority trial. PlaNet-2 compares clinical outcomes in preterm neonates (<34 weeks' gestation at birth) randomised to receive prophylactic platelet transfusions to maintain platelet counts at or above either 25 × 10(9)/l or 50 × 10(9)/l. The primary outcome measure is the proportion of patients who either die or experience a major bleed up to and including study day 28. A total of 660 infants will be randomised.Results And ConclusionsThis trial will help define optimal platelet transfusion support for severely thrombocytopenic preterm neonates by evaluating the risks and benefits of two different prophylactic neonatal platelet transfusion thresholds.© 2014 S. Karger AG, Basel.

26 keywords...

hide…